Evidence map›Paper›PMID 26903543›Full record

ArticleThe Journal of pharmacology and experimental therapeutics2016

Combination of Levo-Tetrahydropalmatine and Low Dose Naltrexone: A Promising Treatment for Prevention of Cocaine Relapse.

Sarah Sushchyk, Zheng-Xiong Xi, Jia Bei Wang

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of pharmacology and experimental therapeutics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.5field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Sarah SushchykDepartment of Pharmaceutical Sciences, University of Maryland Baltimore, Baltimore, Maryland (S.S., J.B.W.); Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse, Intramural Research Program, Baltimore, Maryland (Z.-X.X.).
Zheng-Xiong XiDepartment of Pharmaceutical Sciences, University of Maryland Baltimore, Baltimore, Maryland (S.S., J.B.W.); Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse, Intramural Research Program, Baltimore, Maryland (Z.-X.X.).
Jia Bei WangDepartment of Pharmaceutical Sciences, University of Maryland Baltimore, Baltimore, Maryland (S.S., J.B.W.); Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse, Intramural Research Program, Baltimore, Maryland (Z.-X.X.) jwang@rx.umaryland.edu.
University of Maryland, Baltimore · USNational Institute on Drug Abuse · US

Funding

Dopamine D3 receptor antagonists for treating drug addiction: Preclinical modelsZIADA000473 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI GARDNER, ELIOT · 2009 to 2020
$3.8M
Development of I-THP as New Medication for Drug Addiction (DP1)DP1DA031401 · NIDA · UNIVERSITY OF MARYLAND BALTIMORE · PI WANG, JIA BEI · 2010 to 2015
$3.8M
Intramural NIH HHSNIDA NIH HHS DA-031401NIDA NIH HHS DP1 DA031401
6 · The paper itself

Abstract

Relapse to drug use is often cited as the major obstacle in overcoming a drug addiction. Whereas relapse can occur for a myriad of reasons, it is well established that complex neuroadaptations that occur over the course of addiction are major factors. Cocaine, as a potent dopamine transporter blocker, specifically induces alterations in the dopaminergic as well as other monoaminergic neurotransmissions, which lead to cocaine abuse and dependence. Evidence also suggests that adaptations in the endogenous opioids play important roles in pathophysiology of cocaine addiction. Following this evidence, we investigated a combination medication, levo-tetrahydropalmatine (l-THP) and low dose naltrexone (LDN), targeting primarily dopaminergic and endogenous opioid systems as a cocaine-relapse-prevention treatment. In the present study Wistar rats were used to assess the effects ofl-THP and LDN on cocaine self-administration, drug-seeking behavior during cocaine reinstatement, spontaneous locomotion, and effects on the endogenous opioid system. We determined that the combination ofl-THP and LDN reduces drug-seeking behavior during reinstatement more potently thanl-THP alone. Additionally, the combination ofl-THP and LDN attenuates the sedative locomotor effect induced byl-THP. Furthermore, we revealed that treatment with the combination ofl-THP and LDN has an upregulatory effect on both plasmaβ-endorphin and hypothalamic POMC that was not observed inl-THP-treated groups. These results suggest that the combination ofl-THP and LDN has great potential as an effective and well-tolerated medication for cocaine relapse prevention.

Indexed as

AnimalsBerberine Alkaloidsbeta-EndorphinCocaine-Related DisordersDrug-Seeking BehaviorDrug Therapy, CombinationHypothalamusMaleMotor ActivityNaltrexoneNarcotic AntagonistsPro-OpiomelanocortinRatsRats, WistarRecurrenceSelf AdministrationBerberine Alkaloidsbeta-EndorphinNaltrexoneNarcotic AntagonistsPro-Opiomelanocortintetrahydropalmatine

Identifiers

PMID26903543
PMCPMC4851325
OpenAlexW2324936726

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.